Transcranial Magnetic Stimulation in Parkinson's disease
Phase 4
Recruiting
- Conditions
- PARKINSONG20Parkinson disease
- Registration Number
- DRKS00022356
- Lead Sponsor
- KB
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Parkinson's disease
Exclusion Criteria
atypical Parkinson
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method WHAT improvement of posturale stability<br>WHEN last day of Treatment<br>HOW PosturoMed
- Secondary Outcome Measures
Name Time Method improvement of UPDRS III
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie TMS-induced neural plasticity in the motor cortex of Parkinson's disease (G20) patients?
How does TMS compare to standard-of-care treatments like levodopa in improving UPDRS scores for Parkinson's patients?
Which biomarkers, such as dopamine transporter imaging or alpha-synuclein levels, predict response to TMS in Parkinson's subtypes?
What are the potential adverse events of TMS in Parkinson's disease and their management strategies?
Are there combination approaches using TMS and MAO-B inhibitors for Parkinson's disease treatment?